Fever - Pipeline Review, H2 2012

Global Markets Direct, July 2012, Pages: 46

Fever – Pipeline Review, H2 2012

Summary

Global Markets Direct’s, 'Fever - Pipeline Review, H2 2012', provides an overview of the Fever therapeutic pipeline. This report provides information on the therapeutic development for Fever, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Fever. 'Fever - Pipeline Review, H2 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Fever.
- A review of the Fever products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Fever pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Fever.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Fever pipeline depth and focus of Fever therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Keywords

Fever Therapeutic Products under Development, Key Players in Fever Therapeutics, Fever Pipeline Overview, Fever Pipeline, Fever Pipeline Assessment

2
List of Tables 4
List of Figures 4
Introduction 5
REPORT COVERAGE 5
Fever Overview 6
Therapeutics Development 7
An Overview of Pipeline Products for Fever 7
Fever Therapeutics under Development by Companies 9
Fever Therapeutics under Investigation by Universities/Institutes 10
Late Stage Products 11
Comparative Analysis 11
Mid Clinical Stage Products 12
Comparative Analysis 12
Discovery and Pre-Clinical Stage Products 13
Comparative Analysis 13
Fever Therapeutics – Products under Development by Companies 14
Fever Therapeutics – Products under Investigation by Universities/Institutes 15
Companies Involved in Fever Therapeutics Development 16
Novartis AG 16
NeurogesX, Inc. 17
Ahn-Gook Pharmaceutical Co., Ltd. 18
PLx Pharma Inc. 19
Fever – Therapeutics Assessment 20
Assessment by Monotherapy Products 20
Assessment by Route of Administration 21
Assessment by Molecule Type 23
Drug Profiles 25
Ilaris - Drug Profile 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
NGX-1576 - Drug Profile 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
NGX-9674 - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
NGX-5752 - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
MK-0991 - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
Daptomycin - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
AG NDP803 - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
Micafungin - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
Invaplex 50 Vaccine - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
Daptomycin - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
Fever Therapeutics – Drug Profile Updates 37
Fever Therapeutics – Discontinued Products 39
Fever Therapeutics - Dormant Products 40
Fever – Product Development Milestones 41
Featured News & Press Releases 41
May 22, 2012: PLx Pharma Files New Drug Application For PL2200 Aspirin With FDA 41
Jul 26, 2011: Ceridia Completes Successful Human Clinical Trial 41
May 16, 2011: Caldolor Clinical Study In Hospitalized Burn Patients Published In Journal Of Burn Care & Research 42
Nov 13, 2009: Cadence Pharmaceuticals Announces FDA Extends New Drug Application Review For Intravenous Acetaminophen By Three Months 42
Jul 15, 2009: Cadence Announces Priority Review And Acceptance Of NDA Submission For Acetavance For Treatment Of Acute Pain And Fever 43
May 14, 2009: Cadence Pharmaceuticals Submits Acetavance New Drug Application For Treatment Of Acute Pain And Fever 43
Feb 06, 2009: PLx Receives $0.73 Million In Funding From US Army In SBIR Phase II Award 44
Appendix 45
Methodology 45
Coverage 45
Secondary Research 45
Primary Research 45
Expert Panel Validation 45
Contact Us 46
Disclaimer 46

List of Tables
Number of Products Under Development for Fever, H2 2012 7
Products under Development for Fever – Comparative Analysis, H2 2012 8
Number of Products under Development by Companies, H2 2012 9
Number of Products under Investigation by Universities/Institutes, H2 2012 10
Comparative Analysis by Late Stage Development, H2 2012 11
Comparative Analysis by Mid Clinical Stage Development, H2 2012 12
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2012 13
Products under Development by Companies, H2 2012 14
Products under Investigation by Universities/Institutes, H2 2012 15
Novartis AG, H2 2012 16
NeurogesX, Inc., H2 2012 17
Ahn-Gook Pharmaceutical Co., Ltd., H2 2012 18
PLx Pharma Inc., H2 2012 19
Assessment by Monotherapy Products, H2 2012 20
Assessment by Stage and Route of Administration, H2 2012 22
Assessment by Stage and Molecule Type, H2 2012 24
Fever Therapeutics – Drug Profile Updates 37
Fever Therapeutics – Discontinued Products 39
Fever Therapeutics – Dormant Products 40

List of Figures
Number of Products under Development for Fever, H2 2012 7
Products under Development for Fever – Comparative Analysis, H2 2012 8
Products under Development by Companies, H2 2012 9
Products under Investigation by Universities/Institutes, H2 2012 10
Late Stage Products, H2 2012 11
Mid Clinical Stage Products, H2 2012 12
Discovery and Pre-Clinical Stage Products, H2 2012 13
Assessment by Monotherapy Products, H2 2012 20
Assessment by Route of Administration, H2 2012 21
Assessment by Stage and Route of Administration, H2 2012 22
Assessment by Molecule Type, H2 2012 23
Assessment by Stage and Molecule Type, H2 2012 24

Customers who bought this item also bought

• Acute Pain - Pipeline Review, H2 2012
• Psoriasis - Pipeline Review, H2 2012
• Smoking Cessation - Pipeline Review, H2 2012
• Rheumatoid Arthritis - Pipeline Review, H2 2012
• Other Viral Infections - Pipeline Review, H2 2012
• Obesity - Pipeline Review, H2 2012
• Osteoarthritis - Pipeline Review, H2 2012
• Fatty Liver Disease - Pipeline Review, H2 2012
• Epilepsy - Pipeline Review, H2 2012
• Type 2 Diabetes - Pipeline Review, H2 2012